Hsiang‐Fong Kao

522 total citations
28 papers, 372 citations indexed

About

Hsiang‐Fong Kao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Hsiang‐Fong Kao has authored 28 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Hsiang‐Fong Kao's work include Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Head and Neck Cancer Studies (6 papers). Hsiang‐Fong Kao is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Head and Neck Cancer Studies (6 papers). Hsiang‐Fong Kao collaborates with scholars based in Taiwan, Singapore and United States. Hsiang‐Fong Kao's co-authors include Pei‐Jen Lou, Ruey‐Long Hong, Bin-Chi Liao, Chun‐Nan Chen, Kun‐Huei Yeh, Tseng‐Cheng Chen, Min‐Liang Kuo, Chia‐Wen Liu, Fu‐Chang Hu and Yee‐Chun Chen and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hsiang‐Fong Kao

25 papers receiving 370 citations

Peers

Hsiang‐Fong Kao
Vladimir Kovčin Serbia
Ching-Shan Luo Taiwan
Connie W. C. Hui Hong Kong
Aaron E. Sosa Spain
Ha Linh Vu United States
Mariachiara Santorsola Italy
Marius Žemaitis Lithuania
Yuxin Chu China
Roxana Reyes Spain
Elaine Tan United States
Vladimir Kovčin Serbia
Hsiang‐Fong Kao
Citations per year, relative to Hsiang‐Fong Kao Hsiang‐Fong Kao (= 1×) peers Vladimir Kovčin

Countries citing papers authored by Hsiang‐Fong Kao

Since Specialization
Citations

This map shows the geographic impact of Hsiang‐Fong Kao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsiang‐Fong Kao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsiang‐Fong Kao more than expected).

Fields of papers citing papers by Hsiang‐Fong Kao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsiang‐Fong Kao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsiang‐Fong Kao. The network helps show where Hsiang‐Fong Kao may publish in the future.

Co-authorship network of co-authors of Hsiang‐Fong Kao

This figure shows the co-authorship network connecting the top 25 collaborators of Hsiang‐Fong Kao. A scholar is included among the top collaborators of Hsiang‐Fong Kao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hsiang‐Fong Kao. Hsiang‐Fong Kao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ko, Hui‐Hsin, Wender Lin, Chun‐Kai Fang, et al.. (2025). Sex differences in prognostic factors and genomic variations in oral squamous cell carcinoma: A 5-year retrospective study. Journal of Dental Sciences. 20(2). 1086–1094. 1 indexed citations
2.
Yang, Shih‐Hung, Hsiang‐Fong Kao, Li‐Chun Lu, et al.. (2025). Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma. Journal of the Formosan Medical Association. 125(2). 207–214.
3.
Ko, Hui‐Hsin, Han‐Yi Chou, Hsin‐Han Hou, et al.. (2025). Downregulation of PAX1 in OSCC Enhances Stemness and Immunosuppression via IFIT1 and PD ‐ L1 Pathways. Oral Diseases. 31(7). 2071–2083.
4.
5.
Huang, Yenlin, Yi‐Ju Chen, Hsin-Yi Wu, et al.. (2024). The branched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC. Oncogenesis. 13(1). 36–36. 1 indexed citations
6.
Lim, Wan‐Teck, Hsiang‐Fong Kao, Lisda Suteja, et al.. (2023). Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma. Nature Communications. 14(1). 2781–2781. 25 indexed citations
7.
Kao, Hsiang‐Fong, Bin-Chi Liao, Yenlin Huang, et al.. (2022). Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. Clinical Cancer Research. 28(8). 1560–1571. 53 indexed citations
8.
9.
Yang, Shih‐Hung, Li‐Chun Lu, Hsiang‐Fong Kao, et al.. (2021). Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. OncoImmunology. 10(1). 1973710–1973710. 6 indexed citations
10.
Tsai, Hui‐Jen, Shih‐Hung Yang, Chin‐Fu Hsiao, et al.. (2021). P-140 A phase I study of biweekly abraxane in combination with oxaliplatin and oral S-1/leucovorin as first line treatment for advanced gastric, pancreatic and biliary tract cancers. Annals of Oncology. 32. S146–S147. 1 indexed citations
11.
Chiang, Nai‐Jung, Yan‐Shen Shan, Li‐Yuan Bai, et al.. (2021). TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 39(15_suppl). 4143–4143. 6 indexed citations
12.
Kao, Hsiang‐Fong, et al.. (2021). Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.. Journal of Clinical Oncology. 39(15_suppl). 6024–6024. 3 indexed citations
13.
Lizotte, Patrick H., Ruey‐Long Hong, Troy A. Luster, et al.. (2018). A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunology Research. 6(12). 1511–1523. 69 indexed citations
14.
Kao, Hsiang‐Fong & Ruey‐Long Hong. (2018). Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma. Annals of Oncology. 29. viii379–viii379. 5 indexed citations
15.
Liu, Chia‐Wen, Kuo‐Tai Hua, Kaichun Li, et al.. (2017). Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate–Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics. 16(7). 1421–1434. 48 indexed citations
16.
Kao, Hsiang‐Fong, et al.. (2015). Correlation between plasma EBV DNA and clinical response to pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma. Annals of Oncology. 26. viii5–viii5. 1 indexed citations
17.
Lu, Li‐Chun, Yu‐Yun Shao, Yi‐Hsuan Lee, et al.. (2014). β-Catenin<b><i> (CTNNB1)</i></b> Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma. Oncology. 87(3). 159–166. 39 indexed citations
18.
Kao, Hsiang‐Fong, I‐Chun Chen, Chiun Hsu, et al.. (2014). Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. Supportive Care in Cancer. 22(5). 1189–1197. 11 indexed citations
19.
Chen, I‐Chun, Chiun Hsu, Yee‐Chun Chen, et al.. (2012). Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients. Annals of Oncology. 24(2). 463–468. 34 indexed citations
20.
Li, Ai‐Hsien, et al.. (2011). Aggressive revascularization of acute internal carotid artery occlusion in patients with NIHSS>20 and poor collateral circulation: Preliminary report. International Journal of Cardiology. 161(2). 97–102. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vladimir Kovčin Breakdown of academic impact, for papers by Ching-Shan Luo Breakdown of academic impact, for papers by Connie W. C. Hui Breakdown of academic impact, for papers by Aaron E. Sosa Breakdown of academic impact, for papers by Ha Linh Vu Breakdown of academic impact, for papers by Mariachiara Santorsola Breakdown of academic impact, for papers by Marius Žemaitis Breakdown of academic impact, for papers by Yuxin Chu Breakdown of academic impact, for papers by Roxana Reyes Breakdown of academic impact, for papers by Elaine Tan
Rankless by CCL
2026